Clinical Trial Update: Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase Ib/II study of carboplatin plus M6620 and avelumab in PARP inhibitor-resistant ovarian cancer has completed phase 1 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avelumab (avelumab)
• CARBOPLATIN (Carboplatin)
• M6620 (berzosertib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-11-13